Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.

Seki, Akihiko; Yoshinouchi, Mitsuo; Seki, Nobuhiko; Kodama, Junichi; Miyagi, Yasunari; Kudo, Takafumi

doi:10.3892/ijo.17.1.103

Cited by 10 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[32][33][34] In our experiments, HER2 over-expression was observed in 32 of 111 cases (28.8%), which is only slightly higher. In serous tumor, which accounts for most epithelial ovarian cancer, the rate of HER2 over-expression was 20.8%, whereas in CCA, over-expression was 42.9% in our study (P=0.026).…”

Section: Discussionmentioning

confidence: 87%

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

Fujimura

Katsumata

Tsuda

et al. 2002

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 87%

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

Fujimura

Katsumata

Tsuda

et al. 2002

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…used a hepatocellular carcinoma tissue microarray and found that FGF3 overexpression is significantly associated with hepatocellular carcinoma metastasis and recurrence, suggesting that FGF3 upregulation may play an important role in these processes [35]. Studies have also shown amplification of FGF3 in nasopharyngeal carcinoma [36], ovarian cancer [37], endometrial carcinomas [38], lung cancer [39], and oral cancer [40], [41], [42], [43], which may be important for neoplastic transformation and tumor progression. Here, we first provide evidence that the 3′ UTR of FGF3 physically combines with miR-31*.…”

Section: Discussionmentioning

confidence: 99%

Upregulation of miR-31* Is Negatively Associated with Recurrent/Newly Formed Oral Leukoplakia

et al. 2012

View full text Add to dashboard Cite

BackgroundOral leukoplakia (OLK) is a potentially malignant disorder of the oral cavity. However, the underlying mechanism of OLK is still unclear. In this study, we explore possible miRNAs involved in OLK.Methodology/Principal FindingsUsing miRNA microarrays, we profiled miRNA expression in OLK and malignantly transformed OLK (mtOLK) tissue samples. The upregulation of miR-31*, miR-142-5p, miR-33a, miR-1259, miR-146b-5p, miR-886-3p, miR-886-5p, miR-519d, and miR-301a along with the downregulation of miR-572, miR-611, miR-602, miR-675, miR-585, miR-623, miR-637, and miR-1184 in mtOLK were new observations. Fluorescence in situ hybridization (FISH) analyses confirmed that miR-31* is highly expressed in mtOLK. There was a significant difference between the FISH score (p<0.05) in patients with or without recurrent/newly formed OLK. Functional analyses demonstrated that a miR-31* inhibitor decreased apoptosis in the Leuk-1, which is an immortalized oral epithelial cell line spontaneously derived from an oral leukoplakia lesion. miR-31* regulated apoptosis, cell proliferation, migration, and invasion in the HOIEC, which is a HPV E6/E7-immortalized oral epithelial cell line. Furthermore, miR-31* modulated the biological functions of apoptosis, cell proliferation, cell cycle, migration, and invasion in the oral squamous cell carcinoma cell line, Cal-27. Using bioinformatic analyses and dual luciferase reporter assays, we determined that the 3′ untranslated region of fibroblast growth factor 3 (FGF3) is the target of miR-31*. Expression of FGF3 was downregulated or upregulated in the presence of a miR-31* mimic or inhibitor, respectively.Conclusions/SignificanceUpregulation of miR-31* is negatively associated with recurrent/newly formed OLK. MiR-31* may exert similar but distinguishable effects on biological function in oral cells with different malignant potential. FGF3 is the target of miR-31*. miR-31* may play an important role during OLK progression through regulating FGF3. MiRNA* strands may also have prominent roles in oral carcinogenesis.

show abstract

“…Overexpression of the HER2 receptor in EOC tissue has been associated with poorer prognosis in several studies (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26) , while other studies (27)(28)(29)(30)(31)(32)(33)(34) could not confirm HER2 expression as an independent prognostic factor for survival.…”

mentioning

confidence: 98%

The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

Steffensen¹,

Waldstrøm²,

Jeppesen³

et al. 2007

Int J Gynecol Cancer

View full text Add to dashboard Cite

Both cyclooxygenase 2 (COX2) and human epidermal growth factor receptor 2 (HER2, also called c-erbB-2) overexpression have been related to a worse prognosis in epithelial ovarian cancer (EOC), but the data are conflicting and the percentage of tumors with overexpression varies widely in different studies. The aim of this study was to investigate the potential prognostic value of COX2 and HER2 expression in EOC. A further purpose was to investigate a possible coexpression of the two markers, and finally, to elucidate the agreement between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for evaluation of the HER2 status in EOC. Immunostaining was performed for COX2/HER2 together with FISH analysis for HER2 gene amplification in 160 patients with EOC, FIGO stages IIB-IV. Follow-up was more than 10 years. COX2 overexpression was found in 20.0% of the tumors. With HER2 staining, 64.4% were scored as 0, 24.4% as 1+, 6.9% as 2+, and 4.4% as 3+. Median survival time for COX2-negative tumors was 21.6 versus 36 months for COX2-positive tumors. The longer survival for COX2 positive was significant by both univariate analysis (P= 0.015) and multivariate analysis (P= 0.025). Positive immunostaining for HER2 was associated with poor overall survival (P= 0.03). Agreement between IHC and FISH was seen in all cases (P < 0.0000001). With long-term observation, patients with negative COX2 expression had significantly shorter survival compared to patients with COX2-positive tumors. Positive HER2 expression also notified a grave prognosis, but the low rate of overexpression reduces its potential clinical application.

show abstract

Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.

Cited by 10 publications

References 0 publications

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

Upregulation of miR-31* Is Negatively Associated with Recurrent/Newly Formed Oral Leukoplakia

The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

Contact Info

Product

Resources

About